- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Xetra | 86,960 | 20.06.24 10:46:57 | -0,730 | -0,83% | 86,930 | 86,980 | 86,830 | 87,690 |
|
REGENERON PHARMAC.DL-,001 | 881535 | Frankfurt | 966,200 | 20.06.24 08:07:06 | +2,400 | +0,25% | 969,200 | 978,400 | 966,200 | 963,800 |
